ClinicalTrials.gg
RecruitingNCT07222345Updated Jun 10, 2026

Feasibility of High Intensity Interval Training in Survivors of Childhood, Adolescent, and Young Adult Hodgkin Lymphoma

An interventional study of High Intensity Interval Training (HIIT) in Hodgkin Lymphoma, sponsored by St. Jude Children's Research Hospital. Recruiting at 1 site in United States. Open to participants aged 10 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by St. Jude Children's Research Hospital · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
10 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Hodgkin Disease by St. Jude Children's Research Hospital — 6 open to participants now, 13 under way, none of them phase 3. Hodgkin Disease · St. Jude Children's Research Hospital.

Planned enrollment
13th of 18
20 · median 71
Started
2026
with 2 others
No phase
4 of 27
2 open now
Primary completion
2028-01
later than 8 of 12 live
Registered
25th of 27
by date

Among the 27 studies in Hodgkin Disease by St. Jude Children's Research Hospital, this one is the 13th largest by planned enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2026, is one of 4 with no phase, reaches primary completion later than 8 of the 12 other live ones, and was the 25th registered.

Hodgkin Disease

1,384 studies on the registry are indexed under Hodgkin Disease; 160 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

6 of the 27 studies in Hodgkin Disease by St. Jude Children's Research Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 133 Hodgkin Disease studies recruiting now, 70 (53%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 10 Years to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Hodgkin Disease by St. Jude Children's Research Hospital, or all of them as a file.
02

Study summary

This pilot study evaluates the feasibility of a 12-week high intensity interval training (HIIT) program in survivors of childhood, adolescent, and young adult Hodgkin lymphoma within 24 months of completing treatment. Preliminary efficacy of the HIIT intervention for improved cardiorespiratory fitness, body composition, physical function, autonomic response to exercise, peripheral neuropathy, biological aging markers, and physical activity will also be evaluated.

Primary Objective:

To determine the feasibility of a 12-week high intensity interval training (HIIT) program in survivors of childhood, adolescent, and young adult Hodgkin lymphoma within 24 months of completing treatment.

Feasibility will be assessed by:

  • Participation Rate: Number of eligible survivors approached who enroll.
  • Completion Rate: Number of scheduled HIIT sessions attended and number of enrolled participants who complete post-intervention testing.
Read the detailed description

Hodgkin lymphoma survivors face elevated risks of cardiovascular disease and premature aging. HIIT, which alternates high-intensity effort with recovery periods, has shown benefits in adult cancer survivors but has not been tested in younger populations. This study will assess whether recently treated survivors can complete a remotely supervised 12-week HIIT program and evaluate its effects on multiple health outcomes. Participants will undergo baseline and post-intervention assessments including exercise testing, body composition, autonomic function, and blood biomarkers. The intervention is delivered via a secure web-based platform with live supervision by exercise physiologists.

03

Conditions studied

  • Hodgkin Lymphoma

Browse trials for

Keywords

  • Childhood Cancer Survivor
04

Who can participate

Ages eligible
10 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has been diagnosed with Hodgkin lymphoma between the ages of 10 to 25 years.
  • Participant is between the ages of >10 and \<25 years old the time of enrollment.
  • Participant has completed treatment (end of chemotherapy for those not receiving radiation therapy or end of radiation therapy) for Hodgkin lymphoma within 24 months prior to enrollment and recovered from any acute treatment-related adverse events.
  • Participant has been medically cleared to participate in physical activity.
  • Participant verbalizes understanding of directions for use of the web-based platform on the study provided iPad and heart rate monitor.

Exclusion criteria

Exclusion Criteria:

  • Participant has evidence of disease.
  • Participant has a diagnosis of acute heart failure.
  • Participant reports currently participating in HIIT training or >420 minutes per week of moderate to vigorous physical activity.
  • Female participant who is currently pregnant.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    HIIT Intervention Group

    Participants will complete a 12-week HIIT program with three 25-minute sessions per week. Each session includes warm-up, five cycles of high-intensity intervals (80-95% peak HR) and recovery periods (50-60% peak HR), and cool-down.

    Behavioral: High Intensity Interval Training (HIIT)

Interventions

  • BehavioralHigh Intensity Interval Training (HIIT)

    Participants will complete a 12-week HIIT program with three 25-minute sessions per week. Each session includes warm-up, five cycles of high-intensity intervals (80-95% peak HR) and recovery periods (50-60% peak HR), and cool-down.

06

What researchers measure

Primary outcomes

  1. Participation rate (percent of eligible participants approached who enroll)

    Descriptive statistics will be reported

    Time frame: Trial completion (12 weeks)

  2. Completion rate (percentage of scheduled HIIT sessions attended and percentage of post-intervention testing sessions completed)

    Descriptive statistics will be reported

    Time frame: Trial completion (12 weeks)

Other outcomes

  1. Cardiorespiratory fitness (VO2peak, ml/kg/min)

    Descriptive statistics of the change between baseline and 12 weeks will be reported

    Time frame: baseline at study entry, 12 weeks

  2. Ewing battery score of autonomic function (0 to 5 points)

    Descriptive statistics of the change between baseline and 12 weeks will be reported

    Time frame: baseline at study entry, 12 weeks

  3. Body mass index (weight and height will be combined to report body mass index in kg/m2)

    Descriptive statistics of the change between baseline and 12 weeks will be reported

    Time frame: baseline at study entry, 12 weeks

  4. Percent body fat (%)

    Descriptive statistics of the change between baseline and 12 weeks will be reported

    Time frame: baseline at study entry, 12 weeks

  5. Lean mass percentage (%)

    Descriptive statistics of the change between baseline and 12 weeks will be reported

    Time frame: baseline at study entry, 12 weeks

  6. Visceral fat level (score)

    Descriptive statistics of the change between baseline and 12 weeks will be reported

    Time frame: baseline at study entry, 12 weeks

  7. Hand grip strength (kg)

    Descriptive statistics of the change between baseline and 12 weeks will be reported

    Time frame: baseline at study entry, 12 weeks

  8. Knee extension strength (N/kg)

    Descriptive statistics of the change between baseline and 12 weeks will be reported

    Time frame: baseline at study entry, 12 weeks

  9. Modified total neuropathy scale (0 to 24 points)

    Descriptive statistics of the change between baseline and 12 weeks will be reported

    Time frame: baseline at study entry, 12 weeks

  10. DNA methylation

    Descriptive statistics of the change between baseline and 12 weeks will be reported

    Time frame: baseline at study entry, 12 weeks

  11. Mitochondrial DNA copy number

    Descriptive statistics of the change between baseline and 12 weeks will be reported

    Time frame: baseline at study entry, 12 weeks

  12. Telomere length (kb)

    Descriptive statistics of the change between baseline and 12 weeks will be reported

    Time frame: baseline at study entry, 12 weeks

  13. High-sensitivity C-reactive protein (mg/L)

    Descriptive statistics of the change between baseline and 12 weeks will be reported

    Time frame: baseline at study entry, 12 weeks

  14. Interleukin-6 (pg/mL)

    Descriptive statistics of the change between baseline and 12 weeks will be reported

    Time frame: baseline at study entry, 12 weeks

  15. Physical activity (kilocalories per week)

    Descriptive statistics of the change between baseline and 12 weeks will be reported

    Time frame: baseline at study entry, 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jan 2028, 19 months after the start.

Of 50 non-industry interventional studies with no phase under Hodgkin Disease, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 128. This study's planned 19 months is below that.

Counting every sponsor, half of 53 studies reached it within 42 months; a quarter within 29 and three quarters within 128.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2025
First posted
Oct 29, 2025
StartActual
Jun 8, 2026
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2029
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07222345
Responsible party
Sponsor
First posted
Oct 29, 2025
Start date
Jun 8, 2026
Primary completion
Jan 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
Jun 10, 2026

Study contacts

Amy Berkman, MD
Contact
referralinfo@stjude.org
888-226-4343
Amy Berkman, MD
principal investigator · St. Jude Children's Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion